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age- and sex-matched to the GO group. Concentrations of 
the studied proangiogenic factors in serum samples were 
measured by an enzyme-linked immunosorbent assay 
before (Group A) and after (Group A1) intensive pulse 
i.v.MP treatment and 1 month after the end of additional 
oral MP treatment (Group A2).
Results We found a significant increase in serum concen-
trations of studied factors in the GO group before immuno-
suppressive therapy when compared with the control group 
and decrease after i.v.MP treatment. One month after the 
end of additional oral MP treatment (Group A2), serum 
concentrations of HGF and IL-8 still decreased and no sig-
nificant difference was observed in HGF and IL-8 concen-
trations when compared with the control group. We did not 
find the difference in serum concentration of the studied 
proangiogenic factors between patients in euthyroid and 
hyperthyroid stage of Graves’ disease before MP therapy.
Conclusions Serum HGF and IL-8 concentrations are 
elevated in Graves’ disease patients with active Graves’ 
orbitopathy as compared to the healthy control group. Suc-
cessful management of active Graves’ orbitopathy with glu-
cocorticoids is associated with a decrease in HGF and IL-8 
serum concentrations.
Keywords Graves’ orbitopathy · Hepatocyte growth 
factor · Interleukin-8 · Methylprednisolone treatment
Introduction
Graves’ disease is the most common cause of hyperthy-
roidism, and orbitopathy is the most frequent extrathyroi-
dal manifestation of Graves’ disease [1]. Graves’ orbit-
opathy (GO) is the complex of periocular and/or ocular 
manifestations that are often found in patients with Graves’ 
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disease but also, less frequently, in patients with Hashi-
moto thyroiditis or patients without thyroid abnormalities 
[2]. Graves’ orbitopathy occurs before, during, or after the 
onset of hyperthyroidism and, less frequently, in euthyroid 
or hypothyroid patients. The course of GO can be divided 
into active (infiltrative) and inactive (fibrotic) phases.
The estimated incidence of GO in the general population 
is 16 females and 3 males per 100,000 persons annually, 
with severe forms accounting for no more than 3–5 % of 
the cases [3]. The female-to-male ratio is 9.3:1 in patients 
with mild GO, 3.2:1 in patients with moderate, and 1.4:1 
with severe GO [4].
Graves’ orbitopathy is an autoimmune disease in which 
CD4+ and CD8+ T cells, B cells, plasma cells, and mac-
rophages infiltrate the orbital and periorbital soft tissues, 
which results in tissue remodelling and oedema. Enlarge-
ment of the orbital tissue volume occurs through the accu-
mulation of the extracellular matrix, scar-forming myofi-
broblasts, and/or fat proliferation [5, 6]. Orbital T cells, 
fibroblasts, adipocytes and perhaps other residential cells 
may release numerous cytokines, growth factors, and 
inflammatory mediators, many of which act as potent stim-
ulators of glycosaminoglycan accumulation and oedema 
formation. Numerous cytokines, such as IL-1α, IL-4, IL-6, 
IL-8, IL-10, IL-16, TNF-α, CCL2, and CXCL10 were iden-
tified in the orbital tissue and serum from patients with GO 
and are, therefore, proposed to play a significant role in GO 
pathogenesis [7–10].
The thyroid-stimulating hormone (TSH) receptor 
(TSHR) is the autoantigen responsible for the hyperthy-
roidism in Graves’ disease and is considered an important 
contributor to GO. The major autoantigens in Hashimoto’s 
disease are thyroid peroxidase (TPO) and thyroglobulin 
(Tg). However, these antibodies (anti-TPO and anti-Tg) 
also occur in about 70 % of Graves’ disease patients [11]. 
Thyroid-stimulating hormone receptor antibodies (TRAb) 
are present in all patients with Graves’ disease, and the 
severity and the activity of GO directly correlate positively 
with the blood TRAb levels [12–14].
It is suggested that insulin-like growth factor-1 recep-
tor (IGF-1R) stimulatory autoantibodies enhance the pro-
duction of hyaluronan and T cell chemoattractants (IL-16 
and CCL5) by orbital fibroblasts and/or recruited fibrocytes 
[15]. Other autoantigens were also proposed as putative 
shared antigens, including several eye muscle antigens or 
acetylcholine receptor [16]. It remains to be established 
whether autoimmunity to TSHR is the primary event. How-
ever, the role of other autoantigens in the development of 
GO has not been fully understood as yet.
Angiogenesis, formation of new vascular structures 
from preexisting vessels, occurs in several organs during 
multiple pathophysiological conditions. Although it is an 
integral part of tumour progression, angiogenesis is also 
observed in different inflammatory, fibrotic, and ischaemic 
diseases [17–19].
A limitation in oxygen supply is an important stimulus 
for proangiogenic factors expression. Hypoxia promotes 
the expansion of monoclonal cells, which have lost their 
ability to induce apoptosis in response to hypoxia [20]. 
Lower cellular pH and a higher concentration of lactate 
could induce the release of proangiogenic factors from 
macrophages and tumour cells [21]. In GO, the restricted 
orbital compartment is associated with compression of 
orbital tissue and slow venous return [22]. This may result 
in a limitation in the oxygen supply, lower pH, and a higher 
concentration of lactate which could stimulate the proan-
giogenic factors expression, independently of other mecha-
nisms such as inflammation. Among the mechanical factors 
that trigger angiogenesis, an important role is played by 
increased blood flow in the vascular capillary (e.g. hyper-
thyroidism) [23].
Activators of angiogenesis include vascular endothelial 
growth factor (VEGF), hepatocyte growth factor (HGF), 
transforming growth factor beta 1 (TGFβ1), and its recep-
tors, acidic and basic fibroblast growth factor (aFGF, 
bFGF), insulin-like growth factor I (IGF-I), platelet-derived 
growth factor (PDGF), nitric oxide (NO), plasminogen 
activators (uPA—urokinase plasminogen activator), matrix-
metalloproteinases (MMPs), heparinases, chymases, 
tryptase, cathepsin, angiopoietin-1 (Ang-1) and angiopoi-
etin-2 (Ang-2), plasminogen activator inhibitor 1 (PAI-1), 
angiotensin II, monocyte chemotactic protein 1 (MCP-1), 
hypoxia-inducible factor 1 alpha (HIF-1 α), IL-8 and IL-1, 
epidermal growth factor (EGF), prostaglandin (PGE 1, 
PGE 2, PGF), erythropoietin, histamine, bradykinin, fibrin, 
heparin, and tumour necrosis factor alpha (TNF α) [23, 24].
According to the current guidelines of the European 
Group on Graves’ Orbitopathy, euthyroidism should be 
restored and maintained stably in all patients with GO 
[25, 26]. In the cases of moderate-to-severe GO, intrave-
nous glucocorticoid therapy is the first line treatment [25]. 
Therefore, patient selection and treatment risks must be 
adequately addressed, since available therapies for GO are 
associated with potentially serious adverse effects [27]. 
This is an area where new treatment approaches are greatly 
needed. In previous papers, authors found an important role 
of different proangiogenic factors such as VEGF, PDGF, or 
TGFβ1 in the pathogenesis of GO and its correlation with 
clinical activity of the disease [5, 28–30].
It is known that HGF is a powerful inducer of angiogen-
esis with the activity compared to VEGF [31, 32]. Orbital 
inflammation in active GO is dominated by a T-helper 1 
(Th1) cytokine environment with abundant production of 
cytokines such as IL-1β, IL-2, IFN-γ, and TNF-α and it 
was demonstrated that IL-1β stimulates orbital fibroblasts 
to produce Interleukin-8 (IL-8) which is a chemoattractant 
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for B-lymphocytes, neutrophils, monocytes, and T-lympho-
cytes [33, 34].
The aims of this study were as follows: (1) to evaluate 
the serum concentration of HGF and IL-8 in the blood of 
newly diagnosed Graves’ disease patients with the first epi-
sode of active GO and healthy controls; (2) to estimate the 
influence of the thyroid function (euthyreosis vs. hyper-
thyreosis) on HGF and IL-8 blood levels in patients with 
active GO; (3) to evaluate the influence of intravenous 
methylprednisolone (MP) pulse therapy and additional oral 
MP therapy on HGF and IL-8 blood levels in patients with 
active GO.
The work was supported by the research programme 
(KNW-1-129/K/3/0) of the Committee of Scientific 
Research in Poland.
Patients and methods
Thirty-nine Graves’ disease patients with the first episode 
of clinically active GO (Group A) were enrolled in the 
study. To estimate the influence of the thyroid function on 
serum concentrations of the studied proangiogenic factors, 
Group A was divided into Group A I (n = 18) in euthyroid 
and Group A II (n = 21) in hyperthyroid stage of Graves’ 
disease. The control group consisted of 20 healthy volun-
teers age- and sex-matched to the GO group [mean age 
52.8 ± 7.6, min 34 max 64 years; male/female ratio: 5/15 
(25/75 %)] without thyroid disease, autoimmune diseases, 
liver diseases, or history of immunosuppressive therapy.
All patients enrolled in the GO group were treated with 
anti-thyroid drugs (thiamazole) and mean duration after 
onset of GO was 4.6 months (min 1 month, max 7 months). 
Patients in the studied group were in moderate-to-severe 
stage of GO, according to the European Group on Graves’ 
Orbitopathy classification [25]. Epidemiological and clini-
cal characteristics of the studied group of patients with 
active GO are presented in Table 1.
The inclusion criteria for the study were the following: 
confirmation of Graves’ disease by clinical and laboratory 
findings [free thyroxine—fT4, TSH, TSH-receptor antibod-
ies (TRAb) and, thyroid USG scans—enlargement of thy-
roid gland with typical diffuse increased vascularity] and 
ophthalmological examination confirming the active stage 
of GO (clinical activity score—CAS ≥3 points, magnetic 
resonance scans of the orbit). The exclusion criteria were 
any other causes of exophthalmos, other immune system 
disorders, other metabolic and infectious diseases, previous 
history of immunosuppressive therapy, and patients with 
malignant tumours.
All patients enrolled for the study were diagnosed and 
treated in Endocrinology Division, Department of Patho-
physiology and Endocrinology, Medical University of 
Silesia and GO classification was made by consultant oph-
thalmologist (M.N.) with high experience in diagnosis and 
classifications of GO. In all patients the starting dose 0.5 g 
daily every other day, intravenous (i.v.) methylprednisolone 
(MP) infusion was maintained for the six infusions and 
then, in most cases, halved (0.25 g) for the remaining three 
or six infusions to the total maximum cumulative dose of 
4.5 g (within 3 or 4 weeks). All patients obtained the mid-
dle cumulative dose of i.v.MP according to the recom-
mendations of the EUGOGO [35]. The cumulative dose of 
i.v.MP depended on the clinical response to the treatment 
(ophthalmological assessment performed after six infu-
sions). After i.v.MP therapy, treatment was continued with 
orally administrated MP in the initial dose of 24–32 mg 
daily (0.4 mg/kg of body weight) with dose reduction dur-
ing the next 3 months.
Blood was collected after an overnight fast, and serum 
was obtained by centrifugation and it was stored at −70 °C. 
Concentrations of the studied proangiogenic factors in 
serum samples were measured by an enzyme-linked immu-
nosorbent assay (ELISA) for human HGF (Ray Biotech, 
Inc., USA) and for IL-8 (Quantikine R&D System, USA), 
according to the manufacturer’s standard protocol before 
(Group A) and after (Group A1) intensive pulse i.v.MP 
treatment and 1 month after the end of additional oral MP 
treatment (Group A2). Intra- and interassay variations for 
HGF were 2.9 and 2.6 %, and for IL-8 5.6–6.5 and 6.1–
7.4 %, respectively.
The statistical analysis was performed using the StatSoft 
Inc. (2011) Statistica v.10 data analysis software system. 
The distribution of the tested samples was determined by 
the Kolmogorov–Smirnov test. Kruskal–Wallis one-way 
analysis of variance with post hoc Dunn test was applied 
to compare the results in the studied groups of patients. For 
Table 1  Clinical characteristics of the patients with active Graves’ 
orbitopathy (GO) (Group A) and patients with GO in euthyroid 
(n = 18, Group A I) and hyperthyroid (n = 21, Group A II) stage of 
thyroid function before methylprednisolone treatment
Values are mean ± standard deviation
TRAb TSH-receptor antibodies, CAS clinical activity score of GO, 
NO SPECS severity classification score of GO
Group A (n = 39) Group A I 
(n = 18)
Group A II 
(n = 21)
Age (years) 50 ± 9.4 51 ± 10.7 49 ± 8.4






TRAb (IU/l) 16.776 ± 43.653 7.695 ± 14.726 24.559 ± 57.432
TSH (µIU/ml) 1.467 ± 3.375 3.121 ± 4.481 0.050 ± 0. 077
FT4 (ng/dl) 2.756 ± 7.088 1.168 ± 0.479 4.116 ± 9.542
CAS 5.692 ± 1.127 5.667 ± 1.328 5.714 ± 0.956
NO SPECS 4.079 ± 0.969 4.118 ± 0.781 4.048 ± 1.117
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all statistical tests, a p value <0.05 was considered to indi-
cate statistical significance.
All subjects gave their informed consent before partici-
pating in the study, and the study followed the tenets of the 
Declaration of Helsinki. The project was conducted with 
the approval of The Bioethics Board of the Medical Uni-
versity of Silesia (NN-6501-34/06, KNW/0022/KB/35/13).
Results
The results of the study are presented in Tables 2 and 3 and 
in Figs. 1 and 2.
We found a significant increase in serum concentra-
tions of the studied proangiogenic factors in the GO group 
before i.v.MP therapy when compared with the con-
trol group [HGF: 1035.0 ± 465.0 vs. 567.0 ± 249.0 pg/
ml, p = 0.001; IL-8: 28.89 ± 13.03 vs. 17.57 ± 3.4 pg/
ml, p = 0.0002]. After i.v.MP therapy, we found a signifi-
cant decrease in IL-8 serum concentrations [19.29 ± 4.08 
vs. 28.89 ± 13.03 pg/ml, p = 0.0002] and a decrease 
in HGF though not significant [771.0 ± 295.0 vs. 
1035.0 ± 465.0 pg/ml, p = 0.670] as compared to the con-
centration before treatment.
One month after the end of additional oral MP treat-
ment (Group A2), serum concentration of HGF decreased 
insignificantly compared to the concentration in Group 
A1 [A2: 678.0 ± 345.0 vs. A1: 771.0 ± 295.0 pg/ml; 
p = 1.000]. Serum concentration of HGF was significantly 
lower after the end of additional oral MP treatment (Group 
A2) when compared with the concentration in the GO 
group before i.v.MP therapy (Group A) [678.0 ± 345.0 vs. 
1035.0 ± 465.0 pg/ml, p = 0.021]. After the end of addi-
tional oral MP treatment (Group A2), no significant differ-
ence was observed in HGF concentration when compared 
with the control group [678.0 ± 345.0 vs. 567.0 ± 249.0 pg/
ml, p = 1.000]. Serum concentration of IL-8 also decreased 
after the end of additional oral MP treatment (Group A2) as 
compared with the concentration in Group A1 [16.9 ± 4.82 
vs. 19.29 ± 4.08 pg/ml, p = 0.731], and we found no dif-
ference in the value between Group A2 and the control 
[17.57 ± 3.4 pg/ml, p = 0.994].
In the GO group before i.v.MP therapy, the mean CAS 
score was 5.718 ± 1.123 and we found a significant reduc-
tion in GO activity after i.v.MP (3.0 ± 1.138, p = 0.001) 
and a further significant reduction after the end of addi-
tional oral MP treatment (Group A2) (2.178 ± 1.403, A1 
vs. A2 p = 0.011). Mean severity index of GO measured 
by the NO SPECS score in Group A was 4.077 ± 0.957 
and decreased significantly after i.v.MP therapy (A1: 
3.4 ± 0.976, p = 0.003). In Group A2, we also observed 
a reduction in the severity of GO (2.013 ± 1.276). We did 
not, however, find a significant difference as compared with 
the NO SPECS score in Group A1 (A2 vs. A1 p = 0.099).
Table 2  Serum concentration of hepatocyte growth factor (HGF, pg/ml) in the studied groups of patients with active Graves’ orbitopathy and the 
healthy control group
A patients with clinically active Graves’ orbitopathy (GO) before intensive pulse methylprednisolone treatment, A1 patients with clinically active 
GO after intensive pulse methylprednisolone treatment, A2 patients with clinically active GO 1 month after the end of additional oral methyl-
prednisolone treatment, C control group
Group Mean SD Median Minimum Maximum Lower quartile Upper quartile
A 1035.0 465.0 933.0 312.0 3018.0 663.0 1284.0
A1 771.0 295.0 741.0 162.0 1452.0 582.0 1095.0
A2 678.0 345.0 582.0 216.0 1818.0 459.0 798.0
C 567.0 249.0 432.0 207.0 1203.0 342.0 813.0
Table 3  Serum concentration of Interleukin 8 (IL-8, pg/ml) in the studied groups of patients with active Graves’ orbitopathy and the healthy 
control group
A patients with clinically active Graves’ orbitopathy (GO) before intensive pulse methylprednisolone treatment, A1 patients with clinically active 
GO after intensive pulse methylprednisolone treatment, A2 patients with clinically active GO 1 month after the end of additional oral methyl-
prednisolone treatment, C control group
Group Mean SD Median Minimum Maximum Lower quartile Upper quartile
A 28.89 13.03 24.2 17.4 78.1 19.7 30.1
A1 19.29 4.08 17.9 14.6 29.1 16.9 21.2
A2 16.9 4.82 16.1 11.6 29.8 13.1 19.2
C 17.57 3.4 16.9 12.1 23.6 15.3 20.6
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We did not find the difference in serum concentration 
of the studied proangiogenic factors between patients in 
euthyroid and hyperthyroid stage of Graves’ disease before 
MP therapy (Table 4). Neither did we find any correlation 
between the studied proangiogenic factors and parameters 
of autoimmune thyroid disease such as TRAb.
Discussion
In our previous study, we had found a significant increase in 
serum concentrations of VEGF and PDGF-AA in the group 
with active GO before i.v.MP therapy when compared with 
the control group and a significant decrease in PDGF-AA 
and insignificant decrease in VEGF serum concentrations 
after i.v.MP therapy compared with the concentration 
before treatment. We had found that 1 month after the end 
of additional oral MP treatment, serum concentration of 
PDGF-AA decreased compared to the values after i.v.MP 
treatment and no significant difference was observed in the 
value between Group A2 and the control. However, serum 
concentration of VEGF was still significantly higher as 
compared to the control [5, 30].
In the present study, we found that serum from Graves’ 
patients with clinically active GO exhibited a “proangio-
genic” profile, with enhanced serum levels of HGF and 
IL-8. Concentrations of HGF and IL-8 were significantly 
higher in the studied group before systemic immunosup-
pressive therapy when compared to the control. Further-
more, there was a decrease in the concentration of the stud-
ied proangiogenic factors after intensive MP therapy with 
a simultaneous decrease in the activity and severity of GO 
measured by CAS and NO SPECS score.
Our findings are consistent with several studies demon-
strating an increase in serum concentration of proangio-
genic factors in patients with Graves’ disease [5, 36, 37]. 
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* A vs A2,C
A-patients with clinically active Graves’ orbitopathy (GO) before treatment, A1- patients with clinically active 
GO after intensive pulse methylprednisolone treatment, A2- patients with clinically active GO one month after 
the end of additional oral methylprednisolone treatment, C- healthy control group
 A1 A2 C 
A 0,670344 0,021668 0,000574
A1 - 1,000000 0,109462
A2 - - 1,000000
Fig. 1  Serum concentration of hepatocyte growth factor (HGF, pg/ml) in the studied groups of patients and the significant differences table




















* A vs A1,A2,C
* p<0,05
A-patients with clinically active GO before treatment, A1- patients with clinically active GO after intensive 
pulse methylprednisolone treatment, A2- patients with clinically active GO one month after the end of additional 
oral methylprednisolone treatment, C- healthy control group
 A1 A2 C 
A 0,000176 0,000143 0,000163
A1 - 0,731829 0,884136
A2 - - 0,994079
Fig. 2  Serum concentration of interleukin 8 (IL-8, pg/ml) in the studied groups of patients and the significant differences table
Table 4  Serum concentration of hepatocyte growth factor (HGF) and 
interleukin-8 (IL-8) in the healthy control group (C) and in patients 
with active Graves’ orbitopathy in euthyroid (n = 18, Group A I) and 
hyperthyroid (n = 21, Group A II) stage of thyroid function before 
methylprednisolone therapy
Group n HGF (pg/ml) p
Mean SD Median Min Max C–AI C–AII AI–AII
C 20 567 294 432 432 1203 0.001 0.001 0.746
A I 18 969 363 923 345 1842
A II 21 1101 585 1001 312 3018
Group n Il-8 (pg/ml) p
Mean SD Median Min Max C–AI C–AII AI–AII
C 20 17.565 3.407 16.9 12.1 23.6 0.001 0.001 0.968
A I 18 43.49 74.954 24.1 17.4 367.1
A II 21 31.724 15.354 26.5 18.3 78.1
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However, to the best of our knowledge, our study is the first 
to evaluate HGF concentration in Graves’ disease patients 
with clinically active GO.
Some authors found that serum VEGF level is elevated 
in patients with untreated Graves’ disease and correlates 
positively with the degree of thyroid vascularity assessed 
by colour Doppler ultrasound [37–39]. Other authors found 
elevated concentrations of PDGF, FGF, IGF-1, and TGF-β1 
in patients with GO [28, 29, 38, 39].
Angiogenesis is critical for the growth and metastatic 
spread of tumours and chronic inflammation processes. 
Although HGF is well characterised as a hepatotrophic 
[40] and renotrophic factor [41] in liver and kidney regen-
eration, the presence of the local HGF system (HGF and 
its receptor—cMET) was demonstrated in both endothelial 
cells and vascular smooth muscle cells in vivo and in vitro 
[42]. Hepatocyte growth factor is produced by fibroblasts 
and other stromal cells and accumulates in the extracellu-
lar matrix and in basement membranes, bound to sulphated 
glycosaminoglycans [43, 44]. Serum level of HGF is a 
powerful inducer of angiogenesis [31]. Hepatocyte growth 
factor has an angiogenic action, as well as endothelium-
specific growth action and the effect of HGF is reported 
to be stronger than that of VEGF [31, 45, 46]. Hepatocyte 
growth factor is characterised as an important mitogen 
(stimulation of cell growth), a motogen (stimulation of 
cell motility), and a morphogen (induction of multicellular 
tissue-like structure) [47, 48]. It is also a hypoxia-induced 
secreted protein that binds to cMET and regulates IL-8 
expression.
The biological and clinical significance of HGF and its 
receptor cMET in the thyroid was studied by some authors 
[48–51]. Thus, overexpression of MET protein might rep-
resent an immunohistochemical marker of papillary carci-
noma, potentially helpful in problematic cases [50]. MET 
protein is rarely observed in other thyroid tumours, includ-
ing follicular carcinoma, anaplastic carcinoma, and med-
ullary carcinoma [50, 51]. MET protein is not present in 
normal thyroid follicles, but a moderate expression of MET 
protein is observed in non-neoplastic thyroid diseases, such 
as Graves’ and Hashimoto’s thyroiditis [51], some cases 
of adenomatous goitre, follicular adenoma, and hyper-
functioning goitre [48], which is consistent with our study 
results.
Interleukin-8 was shown to be an angiogenic factor in 
1992 [52]. It plays a significant role in cancerogenesis 
by mediating angiogenesis [53–57]. Additionally, IL-8 
is implicated in a number of inflammatory diseases, such 
as cystic fibrosis [58], adult respiratory distress syndrome 
[59], chronic obstructive pulmonary disease, and asthma 
[60]. Interleukin-8 is secreted by multiple cell types, includ-
ing monocytes, neutrophils, epithelial, fibroblast, endothe-
lial, and mesothelial cells. It is also detected in tissues 
related to Graves’ disease, such as thyroid tissue, orbital 
fibroblasts, and the tears and blood of Graves’ patients [7, 
61, 62]. Interleukin-8 is released from several cell types in 
response to an inflammatory stimulus [63–65] and is cru-
cial for wound healing [66]. Interleukin-8 not only serves 
as a chemotactic factor for leukocytes and fibroblasts but 
it also stimulates fibroblast differentiation into myofibro-
blasts and promotes angiogenesis [67, 68]. Interleukin-8 is 
a chemoattractant for neutrophils and induces expression 
of several cell adhesion molecules and leads to neutrophil 
activation and hence it may contribute to the pathogenesis 
of inflammatory diseases [69, 70].
Interleukin-8 is also an oxidative stress-responsive pro-
inflammatory chemokine, released from epithelial cells fol-
lowing particle-induced oxidative stress leading to neutro-
phil influx and inflammation [71, 72].
Orbital fibroblasts in patients with GO express elevated 
levels of CD40 ligand and it was found that CD40 ligand 
and TSH caused up-regulation of IL-8 concentration in 
orbital fibroblasts of GO patients compared to controls [61, 
73].
Huang et al. found higher concentrations of IL-8 in the 
tears of Graves’ disease patients with GO compared to 
Graves’ disease patients without GO [62]. The concentra-
tion of IL-8 was also increased in the orbital adipose tis-
sue in patients with Graves’ disease and GO compared 
to control patients with Graves’ disease without GO [7]. 
These findings suggest that IL-8 may be a mediator of GO 
activity. Douglas et al. confirmed that stimulation of both 
TSHR and CD40 plays a role in IL-8 production in circu-
lating fibrocytes. These authors concluded that such stimu-
lation may be a significant pathway for IL-8 production in 
Graves’ disease and GO [74].
In our study, we found a significant increase in IL-8 in 
the GO group when compared with the control group and a 
significant decrease after i.v.MP therapy, which is consist-
ent with the results of other authors. One month after the 
end of additional oral MP treatment, serum concentration 
of IL-8 still decreased and we did not find the difference 
with the value in the control group.
Our study supports the observations of Matos et al. who 
found that patients with a positive expression of proangio-
genic factors (FGF, IGF-1, and VEGF) in extraocular eye 
muscles showed CAS greater than 5, thereby suggesting an 
important role of these growth factors in the pathogenesis 
and severity of GO [39].
Glucocorticoids (e.g. MP) modulate VEGF production 
(and probably also other proangiogenic growth factors) and 
Ye et al. found that VEGF levels decreased in patients with 
GO after glucocorticoid treatment, and these changes were 
accompanied by a decrease in CAS. According to these 
authors, this decrease could reflect the degree of orbital 
inflammatory activity [29].
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Recently, authors have demonstrated elevated PDGF 
mRNA expression in the orbital tissue from patients with 
GO [75]. In other studies, authors found that PDGF-BB 
induces the production of IL-6, IL-8, CCL2, CCL5, and 
CCL7 by orbital fibroblasts. The above cytokines are 
involved in the pathogenesis of GO [64]. It is obvious that 
pathological angiogenesis occurs in inflammatory diseases. 
The identification of sensitive and specific markers as 
well as the molecular basis and pathways of diseases with 
increased angiogenesis should be a challenge for further 
research. A better understanding of the process may also 
enable the design of efficient antiangiogenic therapy.
Conclusions
1. Serum HGF and IL-8 concentrations are elevated in 
Graves’ disease patients with active Graves’ orbitopa-
thy as compared to the healthy control group.
2. The elevated serum HGF and IL-8 in patients with 
active Graves’ orbitopathy may reflect long-standing 
autoimmune inflammatory processes in orbital and thy-
roid tissues and intensified angiogenesis.
3. Successful management of active Graves’ orbitopathy 
with glucocorticoids is associated with a decrease in 
HGF and IL-8 serum concentrations.
4. Examination of the proangiogenic factors in the blood 
of patients with Graves’ orbitopathy (in connection 
with clinical signs measured by CAS and orbit MR 
scans) could be one of the parameters in the evalua-
tion of Graves’ orbitopathy activity and response to the 
immunosuppressive treatment, however, further studies 
are still required.
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